Nigrostriatal neuronal death in Parkinson's disease - a passive or an active genetically-controlled process?

被引:0
|
作者
Ziv, I
Barzilai, A
Offen, D
Nardi, N
Melamed, E
机构
[1] BEILINSON MED CTR, DEPT NEUROL, IL-49100 PETAH TIQWA, ISRAEL
[2] BEILINSON MED CTR, FELSENSTEIN RES INST, IL-49100 PETAH TIQWA, ISRAEL
[3] TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, DEPT BIOCHEM, IL-69978 TEL AVIV, ISRAEL
关键词
PROGRAMMED CELL-DEATH; SYMPATHETIC NEURONS; GROWTH-FACTOR; DOPAMINE; APOPTOSIS; INHIBITORS; TOXICITY; 6-HYDROXYDOPAMINE; ACTIVATION; HYPOTHESIS;
D O I
暂无
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The cause for the rather selective degeneration of the nigrostriatal dopaminergic (DA) neurons in Parkinson's disease (PD) is still enigmatic. The major current hypothesis suggests that nigral neuronal death in PD is due to excessive oxidant stress generated by auto- and enzymatic oxidation of DA, formation of neuromelanin and presence of high concentrations of iron. Such cell death is generally regarded as a passive, necrotic process, mainly resulting from membrane lipid peroxidation, leading to its dysfunction and rupture and then to neuronal disintegration. We suggest a novel approach, that views neuronal degeneration in PD as an active process that occurs mainly the nuclear level. Our concept is based on the following observations: (1) Nigral histopathology in PD is characterized by a slow, protracted degeneration of individual neurons. We propose that it may be due to apoptosis [programmed cell-death (PCD), an active, genetically-controlled, intrinsic program of cell ''suicide''] rather than to necrotic cell death. (2) DA exerts antitumor effect on melanoma and neuroblastoma cells. (3) Many anticancer drugs, trigger PCD by causing DNA damage. (4) DA has been shown to be genotoxic. (5) We recently first showed that DA, the endogenous neurotransmitter in the nigra, can trigger apoptosis in cultured, postmitotic sympathetic neurons. (6) We have also shown that PC-12 cells, transfected with the bcl-2 gene (a proto-oncogene that inhibits PCD) are relatively resistant to DA-apoptotic effect. Degeneration of nigrostriatal neurons in PD may therefore be linked to dysregulation of the control mechanisms that normally restrain the PCD-triggering-potential of their own neurotransmitter.
引用
收藏
页码:69 / 76
页数:8
相关论文
共 50 条
  • [41] Reconstruction of the nigrostriatal pathway in a rat model of Parkinson's disease
    Ziemba, Kristine
    Jin, Ying
    Yurek, David
    Smith, George
    JOURNAL OF NEUROTRAUMA, 2007, 24 (07) : 1270 - 1270
  • [42] Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease
    Bohnen, Nicolaas I.
    Gedela, Satyanarayana
    Kuwabara, Hiroto
    Constantine, Gregory M.
    Mathis, Chester A.
    Studenski, Stephanie A.
    Moore, Robert Y.
    JOURNAL OF NEUROLOGY, 2007, 254 (01) : 84 - 90
  • [43] Diffusion Tensor Imaging of the Nigrostriatal Fibers in Parkinson's Disease
    Zhang, Yu
    Wu, I-Wei
    Buckley, Shannon
    Coffey, Christopher S.
    Foster, Eric
    Mendick, Susan
    Seibyl, John
    Schuff, Norbert
    MOVEMENT DISORDERS, 2015, 30 (09) : 1229 - 1236
  • [44] Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease
    Kas, Aurelie
    Bottlaender, Michel
    Gallezot, Jean Dominique
    Vidailhet, Marie
    Villafane, Gabriel
    Gregoire, Marie Claude
    Coulon, Christine
    Valette, Heric
    Dolle, Frederic
    Ribeiro, Maria-Joao
    Hantraye, Philippe
    Remy, Philippe
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2009, 29 (09): : 1601 - 1608
  • [45] Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease
    Bohnen, Nicolaas I.
    Mueller, Martijn L. T. M.
    Zarzhevsky, Natalia
    Koeppe, Robert A.
    Bogan, Christopher W.
    Kilbourn, Michael R.
    Frey, Kirk A.
    Albin, Roger L.
    BRAIN, 2011, 134 : 2358 - 2365
  • [46] Probabilistic tractography study of the nigrostriatal pathway in Parkinson's disease
    Tagliente, S.
    Wilson, H.
    Chappell, Z.
    Yousaf, T.
    De Natale, E.
    Pagano, G.
    MOVEMENT DISORDERS, 2019, 34 : S832 - S833
  • [47] Neuronal vulnerability in Parkinson's disease
    Hirsch, EC
    Faucheux, B
    Damier, P
    MouattPrigent, A
    Agid, Y
    JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 1997, (50): : 79 - 88
  • [48] Neuronal xenotransplantation in Parkinson's disease
    Schumacher, JM
    Isacson, O
    NATURE MEDICINE, 1997, 3 (05) : 474 - 475
  • [49] Neuronal pathology in Parkinson’s disease
    Jörg B. Schulz
    Björn H. Falkenburger
    Cell and Tissue Research, 2004, 318 : 135 - 147
  • [50] Neuronal xenotransplantation in Parkinson's disease
    Robin A. Weiss
    Clive Patience
    Yasuhiro Takeuchi
    Nature Medicine, 1997, 3 : 475 - 475